Transaction · 0000950170-25-032789

Maduck Sean

Maduck Sean, SR, reported a transaction classified as exercise at CORCEPT THERAPEUTICS INC involving 18303.000000 shares for an estimated $92430.15. Reported holdings after the transaction were 103925.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MSR
CORTCORCEPT THERAPEUTICS INC
Filing timeMar 05
Trade dateMar 03, 2025
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

CORT price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
CORT since 2025-03-05Filed 548 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0000950170-25-032789
Common Stock
Transaction date
Mar 03, 2025
Filed Mar 05, 2025, 01:15 AM · 2d delay
Shares
18.3k sh
$505 per share
Estimated value
$9.24M
Computed from shares × price
Holdings after
103k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

See Remarks

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

  2. F2

    The closing price on February 28, 2025 was used to calculate the withholding obligation.

  3. F3

    Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024 and 265 shares underlying unvested restricted stock awards granted to…

  4. F4

    The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 I…

  5. F5

    In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

  6. F6

    Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-y…

  7. F7

    This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.

  8. F8

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $60.58 to $61.055 per share. Information on the exact number of shares sold at each s…

  9. F9

    Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

  10. F10

    Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.

  11. F11

    Exercise ratably in equal installments on each monthly anniversary of February 28, 2025 over a four-year period subject to the Reporting Person's continued service through each vesting date.

  12. F12

    Fully exercisable.

Original filing · 0000950170-25-032789
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

CORT